Chronic Lymphocytic Leukemia Clinical Trial
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Summary
This study is collecting and storing malignant, borderline malignant neoplasms, and related biological samples from young patients with cancer. Collecting and storing samples of tumor tissue, blood, and bone marrow from patients with cancer to study in the laboratory may help the study of cancer in the future.
Full Description
OBJECTIVES:
I. Collect malignant, borderline malignant neoplasms, and related biological specimens from Children's Oncology Group institutions for cases in which there is no disease-specific biologic protocol.
II. Provide a repository for long-term storage of malignant, borderline malignant neoplasms, and related biological specimens from these patients.
III. Make specimens available to qualified researchers to understand the biology of cancer in these patients.
OUTLINE:
Tumor tissue samples, blood, and bone marrow aspirates are collected and stored for future analysis.
Eligibility Criteria
Inclusion Criteria:
Meets any of the following criteria:
Diagnosed with primary neoplasm
Developed a second malignant neoplasm
Any diagnoses having an ICD-O Morphology Code ending in 1, 2, or 3 as listed in the International Classification of Disease for Oncology, Third Edition
Must have biological specimens including solid tumors and leukemias available
Solid tumors meeting the following criteria:
Snap frozen primary tumor OR OCT embedded primary tumor OR formalin fixed (block or tissue in formalin) primary tumor AND at least 10 unstained paraffin slides for NIH Mandated QC (tumors that have undergone central pathology review are allowed)
Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
Pleural fluid or cytologic specimens meeting the following criteria:
At least 1 mL of fluid and at least 2 unstained cytospin slides (or 2 unstained smears)
Slides for pathology review (instead of slides for QC) are required for patients with rare tumors
ALL/AML
3-6 mL of bone marrow aspirate and 10 mL of whole blood
Not eligible for disease-specific biology or banking protocol
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.